miRNAs在HBV感染及肝癌发病中的作用

doi:10.3969/j.issn.1672-5069.2016.03.035

Abstract

Wang Yi,Yang Zhenhua. Role of miRNAs in HBV infection and hepatocarcinogenesis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(3): 381-384.

[1] Lin CL， Kao JH. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomed Sci， 2008， 15(2): 137-145.
[2] Hammond S M. MicroRNAs as oncogenes. Curr Opin Genet Dev，2006，16 (1):4-9.
[3] Zamore PD， Haley B. Ribo-gnome: the big world of small RNAs. Science， 2005， 309(5740):1519-1524.
[4] Lee EJ， Gusev Y， Jiang J et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer， 2007， 120(5):1046-1054.
[5] Calin GA， Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer，2006， 6 (11):857-866.
[6] George GP， Mittal RD. MicroRNAs: Potential biomarkers in cancer. Indian J Clin Biochem， 2010， 25 (1):4-14.
[7] Yang JD， Roberts LR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am， 2010， 24(4):899-919.
[8] Huang XB， Li J， Zheng L， et al. Bioinformatics analysis reveals potential candidate drugs for HCC. Pathol Oncol Res， 2013， 19(2):251-258.
[9] Zhou Y， Wang S， Ma JW， et al. Hepatitis B virus protein X-induced expression of the CXC chemokine IP-10 is mediated through activation of NF-κB and increases migration of leukocytes . J Biol Chem， 2010， 285(16):12159-12168.
[10] Lepere-Douard C， Trotard M， Le Seyec J， et al. The first transmembrane domain of the hepatitis B virus large envelope protein is crucial for infectivity. Virology， 2009， 83 (22):11819-11829.
[11] Wu G， Yu F， Xiao Z， et al. Hepatitis b virus x protein downregulates expression of the mir-16 family in malignant hepatocytes in vitro . Br J Cancer， 2011， 105 (1):146-153.
[12] Connolly E， Melegari M， Landgraf P， et al. Elevated expression of the mir-17-92 polycistron and mir-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol， 2008， 173(3):856-864.
[13] Gao P， Wong CC， Tung EK， et al. Deregulation of microrna expression occurs early and accumulates in early stages of hbv-associated multistep hepatocarcinogenesis. J Hepatol， 2011， 54(6):1177-1184.
[14] Sheng Y， Ding S， Tang H， et al. Functional analysis of miR-101-3p and Rap1b involved in hepatitis B virus-related hepatocellular carcinoma pathogenesis. Biochem Cell Biol， 2014， 92(2):152-162.
[15] Wei Y， Neuveut C， Tiollais P， et al. Molecular biology of the hepatitis B virus and role of the X gene. Pathol Biol， 2010，58 (4):267-272.
[16] Lecellier CH， Dunoyer P， Arar K， et al. A cellular microrna mediates antiviral defense in human cells. Science， 2005， 308(5721):557-560.
[17] Zhang GL， Li YX， Zheng SQ， et al. Suppression of hepatitis b virus replication by microrna-199a-3p and microrna-210. Antiviral Res， 2010， 88(2):169-175.
[18] Chen Y， Shen A， Rider PJ， et al. A liver-specific microRNA binds to a highly conserved RNA sequence of hepatitis b virus and negatively regulates viral gene expression and replication . FASEB J， 2011， 25(12):4511-4521.
[19] Grundhoff A， Sullivan CS. Virus-encoded microRNAs. Virology， 2011，411 (2): 325-343.
[20] Vivekanandan P， Daniel HD， Kannangai R， et al. Hepatitis B virus replication induces methylation of both host and viral DNA. Virology， 2010，84 (9):4321-4329.
[21] Belloni L， Pollicino T， De Nicola F， et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci U. S. A， 2009，106(47):19975-19979.
[22] Quasdorff M， Protzer U. Control of hepatitis B virus at the level of transcription. Viral Hepat， 2010， 17(8):527-536.
[23] Wang J， Liu X， Wu H， et al. CREB upregulates long non-coding RNA， HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res， 2010， 38(16):5366-5383.
[24] Han H， Sun D， Li W， et al. A c-myc-microrna functional feedback loop affects hepatocarcinogenesis. Hepatology， 2013， 57(6):2378-2389.
[25] Qiu X， Dong S， Qiao F， et al. Hbx-mediated mir-21 upregulation represses tumor-suppressor function of pdcd4 in hepatocellular carcinoma. Oncogene， 2013， 32(27):3296-3305.
[26] Wang Y， Lu Y， Toh ST， et al. Lethal-7 is down-regulated by the hepatitis bvirus x protein and targets signal transducer and activator of transcription 3. J Hepatol， 2010， 53(1):57-66.
[27] Li Y， Xie J， Xu X， et al. MicroRNA-548 down-regulates host antiviral response via direct targeting of ifn-lambda1. Protein Cell， 2013， 4(2):130-141.
[28] Xie Q， Chen X， Lu F， et al. Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sex-determining region y box 6 in hepatocellular carcinoma. Cancer， 2012， 118(9):2431-2442.
[29] [Mahajan VS， Drake A， Chen J. Virus-specific host miRNAs: Antiviral defenses or promoters of persistent infection? Trends Immunol， 2009， 30(1):1-7.
[30] Wang S， Zhang X， Ju Y， et al. Microrna-146a feedback suppresses t cell immune function by targeting stat1 in patients with chronic hepatitis B. J Immunol， 2013， 191(1):293-301.
[31] Yang P， Li QJ， Feng Y， et al. Tgf-beta-mir-34a-ccl22 signaling-induced treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell， 2012， 22(3): 291-303.
[32] Waidmann O， Bihrer V， Pleli T， et al. Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection. J Viral Hepat， 2012， 19(2):e58-e65.
[33] Jia Y， Liu H， Zhuang Q， et al. Tumorigenicity of cancer stem-like cells derived from hepatocarcinoma is regulated by microRNA-145. Oncol Rep， 2012， 27 (6):1865-1872.
[34] Karakatsanis A， Papaconstantinou I， Gazouli M， et al. Expression of microRNAs， miR-21， miR-31， miR-122， miR-145， miR-146a， miR-200c， miR-221， miR-222， and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog， 2013， 52 (4):297-303.
[35] Yamamoto Y， Kosaka N， Tanaka M， et al. MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers， 2009， 14 (7):529-538.

Role of miRNAs in HBV infection and hepatocarcinogenesis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[2]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[3]	Zhu Jun, Ding Ying, Wang Shiqing, et al. Peripheral blood Th22 cells and plasma interleukin-22 level changes in patients with hepatocellular carcinoma after hepatectomy and administration of ulinastatin [J]. Journal of Practical Hepatology, 2019, 22(5): 720-723.
[4]	Wang Gang, Zhao Hongbo, Zhu Yaling, et al. Cancerous XPO5 gene level in patients with hepatocellular carcinoma and its clinical significance [J]. Journal of Practical Hepatology, 2019, 22(5): 724-727.
[5]	Qiao Zhizhong. Value of contrast-enhanced ultrasonography in differential diagnosis of patients with focal nodular hyperplasia and hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 421-424.
[6]	Zhu Guangxi，Wen Liangzhi，Chen Dongfeng. Pathogenesis of non-alcoholic fatty liver disease-related hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 453-456.
[7]	Wang Huming, Fan Dongsheng, Xu Jie, Liu Xianfegn, Zhou Ning, Li Min, Bao Nana. Cancerous miRNA-30c levels affecting the survival of patients with hepatocellular carcinoma after hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 248-251.
[8]	Xing Diankui, Cheng Jing. Clinical value of ¹⁸F-FDG PET/CT scan in patients with hepatocellular carcinoma and hepatic microvascular invasion [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 252-254.
[9]	Wang Xiuqing, Ma Yanjun, Zhan Jinli. Efficacy of transcatheter arterial chemoembolization and ultrasound-guided microwave ablation in the treatment of patients with hepatocellular carcinoma at special sites [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 260-263.
[10]	Zhang Xiaozhou, Shuai Ling, Wang Qingda, Yang Nan. Changes of serum miR-335 levels in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 268-271.
[11]	Wang Zhaoxia, Guan Ke, Fu Sanxian, Wang Huijie. Early administration of enteral nutrition in patients with hepatocellular carcinoma undergoing hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 272-275.
[12]	Zhao Xitai, Nie Qinghe. Serum microRNA in diagnosis of patients with hepatocellular carcinoma and methodological progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 297-300.
[13]	Fan Jiangao.. Highlights of Journal of Practical Hepatology in 2018 [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 1-3.
[14]	Chen Yongqi, Chen Qian, Yuan Chunyan, et al.. Cancerous and noncancerous expression of Ep-CAM and C-Kit in patients with hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 109-112.
[15]	Ouyang Shi, Chen Xiaoping, Cheng Tao, et al.. Correlation of HLA-A,-B,-C,-DRB1,-DQB1 alleles to hepatocellular carcinoma development in patients with hepatitis B viral infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 940-946.